NCT05140512View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

September 15, 2021

Study Completion Date

November 26, 2021

Conditions
Prostate Cancer
Interventions
DRUG

LY01005

LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.

DRUG

ZOLADEX® 3.6 mg

ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.

Trial Locations (1)

Unknown

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT05140512 - Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | Biotech Hunter | Biotech Hunter